The China game behind US$1.25 billion: PF-08634404 (SSGJ-707) China oncology strategy panorama

Breaking this asset down across each checkpoint of China registration, access and commercialization, eight cards lay out the risk distribution:

Most MNCs registering in China use a hybrid package of "global core evidence + China bridging + subgroup consistency", but SSGJ-707 doesn't need to — its Chinese P3 is a complete local RCT, reading out 12–18 months ahead of the global Symbiotic series. This is an unusual "reverse synchronization":

On choice of accelerated pathway, the most likely joint Pfizer–3SBio strategy is:

PD-L1 is this product's only identifying biomarker, but IHC testing penetration in China is uneven, the NRDL price anchor on the payment side has been set by a same-class product, and much of physicians' educational attention has already been captured by ivonescimab. None of the three rings is a dead knot, but none is a tailwind:

Some real-world data on the testing end: in 2025 the PD-L1 IHC testing rate among Chinese NSCLC patients was about 60–70% (leading tertiary hospitals), but only 30–50% in county/city hospitals, with the 22C3 antibody clone having the broadest coverage, followed by SP263. This product's P3 uses 22C3 IHC by default — consistent with ivonescimab and highly compatible with pembro, minimizing testing concordance issues at commercialization. But PD-L1 LDTs in small and mid-sized hospitals still have gray areas in section quality, positive/negative interpretation and inter-laboratory concordance, creating a 10–20% "missed identification rate" for clinical translation of a narrow-population label (TPS≥1%). Solving this requires Pfizer's medical affairs team to partner with testing companies (Roche Diagnostics, Dako/Agilent) on downstream education — a key part of first-year launch spending.

SSGJ-707 China registration and commercialization scenarios

The core variable behind the scenarios is the timing of Pfizer's exercise of the China option. If exercised before the P3 primary endpoint readout (2026 H1–H2), Pfizer can start MAH preparation, KOL network linkage and NRDL economic modeling in H2 2026 — laying commercial groundwork for launch immediately after priority review in 2027 Q3. If the decision is delayed until after the readout, Pfizer will miss about 6–12 months of pre-launch window, and the neutral scenario becomes the baseline. Although 3SBio has independent commercialization capability (its oncology commercial network built around ixekizumab/cipterbin has taken shape), it lacks MNC-grade depth of nationwide medical promotion, which will show directly in the speed of hospital access.

The scenario boundaries also require a set of numbers: China has about 300,000 new 1L PD-L1+ EGFRm/ALK- NSCLC patients a year; assuming SSGJ-707 captures 15–20% share within two years of launch (optimistic), that corresponds to 45,000–60,000 patients treated per year; at an estimated annual post-NRDL treatment cost of RMB 60,000, peak annual sales in China would be about RMB 2.7–3.6 billion (about US$400–500 million). This is the China portion of the 5–7-year payback period on Pfizer's US$1.25 billion upfront (the rest from the US, Europe and Japan). If the China option is not exercised, Pfizer forgoes this roughly 1/3 of global revenue, but also saves the US$150 million option fee and about US$200–300 million of China infrastructure investment over the next 5 years — the core trade-off in Pfizer BD finance's ROI model. But as long as Pfizer is determined to build SSGJ-707 into a backbone (rather than a pure NSCLC single-point asset), losing China means losing the largest data pool for validating the backbone globally — a strategic loss harder to quantify than a financial one.

Comparison of review pace for PD-1×VEGF bispecifics in China

Interpretation: in China's PD-1×VEGF bispecific sequence, SSGJ-707 is the second leg (about 24–30 months behind ivonescimab in approval), but a length ahead of BNT327/JS207/HB0025. This position is the most awkward: it can neither enjoy the 12–24-month exclusivity window of first-in-class, nor compete on price as a "cheap domestic follower" (Pfizer's global commercial system means its price floor is higher than domestic followers'). The only way to survive is to use Pfizer's unique asset matrix (Padcev / Elahere / Dato-DXd via the Daiichi Sankyo partnership) to package SSGJ-707 as a backbone, rather than as a monotherapy PD-1×VEGF player. This is what Pfizer's global strategic framing (replace Keytruda) really means in the Chinese market — not replacing Keytruda monotherapy, but replacing the "Keytruda plus everything" standard.

Worth noting is that ivonescimab has unresolved questions of its own: Summit-led global P3s such as HARMONi-3 (SCC NSCLC) and HARMONi-6 have not yet read out, and the FDA path is still under stress test; and market expectations for Akeso fluctuated significantly in H2 2025 due to delayed OS signals. This means the ivonescimab SSGJ-707 faces in 2027–2028 may not be the unshakable benchmark imagined in 2026, but an opponent still defending its OS, FDA and backbone story. SSGJ-707's best tactic in China is to enter 1L with PFS data, enter 1L all-PD-L1 with ADC combinations, and establish a differentiated label in the 2L post-EGFR-TKI resistance setting — the latter two being positions where ivonescimab's data are still incomplete.

Interpretation: this asset has undergone a governance leap from a Chinese domestic bispecific to a global big-pharma drug. In two years, SSGJ-707 moved from a Hong Kong–listed biotech whose valuation depended on a single lung cancer asset to an MNC with 30+ oncology pipeline programs, a global network and a marketing machine — but the Chinese market was left to the originator. This is a rare "first half originated, second half licensed, last mile back to the originator" structure: 3SBio retains China commercial rights (until Pfizer exercises the option). Any delay in decision-making costs Pfizer China launch readiness time.

There is another layer of structural tension worth pointing out. The public part of the 3SBio–Pfizer collaboration terms is relatively concise, but the implied collaborative terms necessarily involve: (1) rights to use the Chinese P3 data — after readout, can Pfizer use them directly to support ex-China registration? This is a reverse case of overseas acceptability; (2) the timetable for dual-site CMC switching — after Pfizer exercises the option, is 3SBio's Shenyang plant a CMO or does it exit? (3) co-promotion arrangements — if Pfizer exercises the option, can 3SBio keep a share of medical promotion? The specific form of these terms determines the actual executing party in China in 2026–2028. One public breakdown: if Pfizer exercises the option in 2026 H2, the 2027 China launch would most likely be led by Pfizer's oncology business unit for sales, medical affairs and access, with 3SBio as designated CMO + co-marketing partner retaining specific regions (possibly parts of Northeast and North China). If not exercised, 3SBio's NSCLC commercial team would need to re-expand and bolster its ADC-combination medical capability — itself a 6–12-month project.

Pulling the view from neutral forecasts to extreme boundaries makes SSGJ-707's odds structure in China clearer. Three pairs of contrasts are listed here, each containing an upside trigger and a downside trigger, together forming a complete asymmetric risk map.

Pair one: the Chinese P3 PFS signal. Upside: PFS HR ≤ 0.50, better than ivonescimab's HARMONi-2 HR of 0.51, with all key subgroups (TPS≥50%, TPS 1–49%, sex, age) consistent — this would immediately earn SSGJ-707 a CSCO guideline Level I recommendation and push ivonescimab back into a pick-one-of-two position. Downside: PFS HR 0.65–0.80, signal in the right direction but effect size insufficient to differentiate, compounded by a weaker-than-expected OS tail; the product is cut below RMB 40,000/year in NRDL negotiation and loses the support of Pfizer's global backbone story — which could only be rescued by the global P3 Symbiotic-Lung-01 in 2027–2028.

Pair two: Padcev combination data. Upside: Chinese-site data from Symbiotic-GU-06 (UC + Padcev) read out first, with ORR >60% and manageable overlapping irAEs — the product gains differentiated labels in UC and EC that ivonescimab can never get (Akeso has no ADC matrix), and Pfizer proves the synergy hypothesis of PD-1×VEGF with a vedotin payload. Downside: stacked irAEs with Padcev (especially skin toxicity, neurotoxicity, hyperglycemia), grade ≥3 AEs exceeding 50%, requiring lower combination doses — this would heavily discount the "backbone with ADC" story, and SSGJ-707 would fall back to a pure NSCLC player.

Pair three: China option and governance structure. Upside: Pfizer exercises the China option in 2026 Q3 and signs a complete co-promotion + CMO agreement with 3SBio — 3SBio retains medical promotion (especially toward its long-standing oncology PI network), Pfizer handles commercial insurance, hospital access and NRDL negotiation — maximizing complementary capabilities without adding channel conflict. Downside: Pfizer only exercises the option after 2027; in the meantime 3SBio commercializes alone but with insufficient medical depth, further entrenching ivonescimab as the only PD-1×VEGF standard; after option exercise, integrating 3SBio and Pfizer channels takes 6–12 months, compressing the window from a 2027 Q3 launch to 2028 H1, and with the 2027 NRDL window missed, first reimbursement is pushed to 2028 Q4.

Taken together, SSGJ-707's odds in China are not symmetric — downside risk is heavy (50–60% probability of landing in the neutral or pessimistic case), and the upside requires several triggers to happen simultaneously (strong P3 data + successful Padcev combination + timely option exercise). But if all upside triggers hit, SSGJ-707 could become the flagship asset of Pfizer China's oncology unit for 2027–2030, with peak sales potentially above RMB 3 billion, paving the way for Pfizer to promote its ADC matrix such as Dato-DXd and Elahere in China. This is a "win big or be mediocre" asset rather than "win small, lose big" — the opposite of the typical odds distribution for MNC licensed-in assets.

From a higher vantage point, SSGJ-707 is one of the most representative assets of the 2024–2025 wave of Chinese innovative drugs going global: originated on a Chinese domestic platform, its global rights transferred to an MNC via a license-out deal while the domestic market was retained; its Chinese clinical data flow outward to the world, becoming one of the pillars of Pfizer's global Phase 3 portfolio; and its registration strategy in China follows a China-first standalone RCT path rather than the "global approval first, China bridging" that MNCs were used to. This reverse data flow + dual-owner governance structure is becoming a new paradigm for Sino-US innovative drug collaboration, and SSGJ-707 is an early experiment in it. However it performs in 2027–2028, the results of the experiment itself will be used by Sanofi, Roche, BMS, Merck and other MNCs to reassess their own China BD strategies — this is also the "hidden asset" Pfizer's US$1.25 billion is really buying: a specimen for validating the future China-out + Pfizer-in cross-border collaboration paradigm. In this sense, SSGJ-707's China strategy concerns not only the fate of one PD-1×VEGF bispecific, but also a signpost for the direction of collaboration models between Chinese innovative drug companies and MNCs over the next five years.

Finally, back to a simple question: if you were Pfizer China's head of oncology, what should you do today, May 2026? The answer is not to wait for ASCO 2026 data, nor for the July interim readout of the Chinese P3 — but to finish both the "if it hits" and "if it misses" plans before the data come out. Hit scenario: exercise the option immediately + dual-site MAH + Padcev combination expansion + head-to-head ivonescimab design — standard moves 18 months before launch that cannot be pushed until after the readout. Miss scenario: don't exercise the option + 3SBio carries the load alone + Pfizer falls back on the global Symbiotic data as its only commercial asset — which requires the China team to negotiate allocation of responsibilities with 3SBio in advance, rather than switching on the fly. Making choices ahead of uncertainty is the scarcest capability in MNC China strategy, and the last threshold for whether Pfizer's US$1.25 billion earns a return.